DOCSLIB.ORG

Pharmaceutical Reform Pharmaceutical Reform Is Available As an Interactive Textbook at .Worldbank.Org/Pdt

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharmaceutical Reform Pharmaceutical Reform Is Available As an Interactive Textbook at .Worldbank.Org/Pdt Public Disclosure Authorized Public Disclosure Authorized Public Disclosure Authorized Public Disclosure Authorized A Guide to ImprovingEquity and Performance Reform Pharmaceutical http://www.worldbank.org/pdt Interactive textbook at textbook Interactive Michael R.Reich J.Robertsand Marc Pharmaceutical Reform Pharmaceutical Reform is available as an interactive textbook at http://www .worldbank.org/pdt. The electronic version allows communities of practice and colleagues working in sectors and regions, as well as students and teachers, to share notes and related materials for an enhanced, multimedia learning and knowledge-exchange experience. Pharmaceutical Reform A Guide to Improving Performance and Equity Marc J. Roberts and Michael R. Reich THE WORLD BANK Washington, D.C. © 2011 The International Bank for Reconstruction and Development / The World Bank 1818 H Street NW Washington DC 20433 Telephone: 202-473-1000 Internet: www.worldbank.org All rights reserved 1 2 3 4 :: 14 13 12 11 This volume is a product of the staff of the International Bank for Reconstruction and Development / The World Bank. The fi ndings, interpretations, and conclusions expressed in this volume do not necessarily refl ect the views of the Executive Directors of The World Bank or the governments they represent. The World Bank does not guarantee the accuracy of the data included in this work. The boundaries, colors, denominations, and other information shown on any map in this work do not imply any judgement on the part of The World Bank concerning the legal status of any territory or the endorsement or acceptance of such boundaries. Rights and Permissions The material in this publication is copyrighted. Copying and/or transmitting portions or all of this work without permission may be a violation of applicable law. The International Bank for Reconstruction and Development / The World Bank encourages dissemination of its work and will normally grant permission to reproduce portions of the work promptly. For permission to photocopy or reprint any part of this work, please send a request with complete information to the Copyright Clearance Center Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; telephone: 978-750-8400; fax: 978-750-4470; Internet: www.copyright.com. All other queries on rights and licenses, including subsidiary rights, should be addressed to the Offi ce of the Publisher, The World Bank, 1818 H Street NW, Washington, DC 20433, USA; fax: 202-522-2422; e-mail: [email protected]. ISBN 978-0-8213-8760-3 eISBN 978-0-8213-8771-9 DOI 10.1596/978-0-8213-8760-3 Library of Congress Cataloging-in-Publication Data Roberts, Marc J. Pharmaceutical reform : a guide to improving performance and equity / by Marc J. Roberts and Michael R. Reich. p. ; cm. Includes bibliographical references and index. ISBN 978-0-8213-8760-3 — ISBN 978-0-8213-8771-9 (eISBN) 1. Pharmaceutical policy. 2. Pharmaceutical industry. 3. Health care reform. I. Reich, Michael, 1950- II. World Bank. III. Title. [DNLM: 1. Drug Industry—organization & administration. 2. Health Care Reform— organization & administration. 3. Pharmaceutical Preparations. QV 736] RA401.A1R63 2011 615.1—dc22 2011012020 CONTENTS Foreword xi Preface xiii Acknowledgments xix Chapter 1. Introduction 1 Why Care about Pharmaceutical Policy? 1 What Is Pharmaceutical Policy? 5 What the Book Seeks to Accomplish 7 References 9 Chapter 2. Using the Flagship Framework to Reform Pharmaceutical Policy 11 How to Begin the Process of Reform 11 Ultimate Performance Goals 13 The Role of Cost in Setting Reform Goals 17 The Role of Politics and Ethics in Identifying Problems and Choosing Reform Priorities 20 The Reform Cycle 22 The Control Knobs 24 Government Failures and Market Failures 26 Summary on the Flagship Framework 32 References 33 Chapter 3. Introduction to the Pharmaceutical Sector 35 The World Pharmaceutical Market 35 Consolidation of Research and Development Companies 42 Pharmaceutical Pricing 44 The Role of National Policy 47 Summary on the Pharmaceutical Sector 50 References 51 v Chapter 4. Ethics and Priority Setting in Pharmaceutical Reform 53 Commonly Identifi ed Pharmaceutical Sector Problems 55 Relating Identifi ed Problems to Performance Goals 56 Relating Performance Goals to Ethical Perspectives: Utilitarianism 58 Relating Performance Goals to Ethical Perspectives: Liberalism 61 Relating Performance Goals to Ethical Perspectives: Communitarianism 63 The Flagship Framework and Economic Development Goals 66 The International Dimension of Pharmaceutical Policy 67 The Importance of Fair Process 69 Summary on Ethics (and Some Suggestions) 70 Case Studies for Chapter 4 (Ethics) 71 References 72 Chapter 5. Diagnosing Performance Problems and Developing a Policy Response 75 A Simple Pharmaceutical Example to Illustrate the Method 77 The Intermediate Performance Goals and Their Role in the Diagnostic Process 79 Using the Intermediate Performance Measures 82 A Systems Approach to Process Improvement 84 Developing Policy Responses 85 Summary on Diagnosis 87 References 88 Chapter 6. Managing the Politics of Pharmaceutical Policy Reform 89 The Role of Politics in Pharmaceutical Policy Making 89 Stakeholder Analysis and Political Context 91 Moving to Strategy Development 93 The Politics of Pharmaceutical Policy Reform—Some Examples 96 Summary on Politics 98 Case Study on Politics 98 References 98 Chapter 7. Financing the Pharmaceutical Sector 101 Pharmaceutical Financing and Health Sector Financing 102 Judging the Distributional Impact of Financing Options 103 Pharmaceutical Financing Choices 115 Summary on Financing 118 Case Study on Financing and Payment 119 References 119 vi Contents Chapter 8. Paying for Pharmaceuticals 121 Pharmaceutical Payment Reform and Health Sector Reform 122 Pharmaceutical Payment and Corruption 123 Procurement 124 Wholesale Payments 129 Payments by End Users 133 Summary on Payment 139 Case Studies on Financing and Payment 140 References 140 Chapter 9. Organizing the Public Sector to Improve Pharmaceutical Performance 143 Pharmaceutical Sector Performance: The Six Keys 144 Autonomy, Corporatization, and Marketization 149 Contracting In and Contracting Out 151 Decentralization 152 Social Franchising 154 Using the New Public Sector Management 156 Essential Medicines Lists 157 The Potential Contribution of Process Improvement 158 The Challenges of Change 160 Summary on Organization 161 Case Studies on Organization 162 References 162 Chapter 10. Improving Pharmaceutical Sector Performance through Regulation 165 The Conditions for Successful Regulation 167 Regulating Product Quality 170 Regulating Use 176 Regulation Directed at Controlling Prices 178 Summary on Regulation 179 Case Studies on Regulation 180 References 180 Chapter 11. Using Persuasion to Infl uence Pharmaceutical Use 181 Elements of Human Decision Making 181 Using Persuasion: The Lessons of Social Marketing 184 Changing Behavior in the Pharmaceutical Sector 187 Summary on Persuasion 192 Case Studies on Persuasion 193 References 193 Contents vii Chapter 12. Conclusions 195 Thinking about Pharmaceutical Systems 195 Steps in the Process 196 Final Thoughts 198 Case Study A. Defi ning an Essential Medicines List in Sudamerica 201 Case Study B. Registering Misoprostol in Sri Lanka 211 Case Study C. Disentangling Prescribing and Dispensing in the Republic of Korea 225 Case Study D. Last Mile Logistics for Essential Drugs: The Case of Zambia 235 Case Study E. Drug Procurement in East Africania 247 Case Study F. Converting Basic Drug Shops to Accredited Drug Dispensing Outlets in Tanzania 255 Case Study G. Counterfeit Medicines in Nigeria 267 Case Study H. Changing the Use of Antibiotics in Peru 279 Case Study I. Preparing for Microbicide Introduction in South Africa 289 Case Study J. Drug Coverage in Ghana’s National Health Insurance Scheme 301 Index. 321 Figures 1.1 The Pharmaceutical System 5 2.1 The Flagship Framework for Health System Performance 16 2.2 Cost-Performance Trade-Offs 17 2.3 The Reform Cycle 22 3.1 Growth Forecasts for Global Pharmaceutical Sales by Region 36 3.2 Distribution of Population and Total Pharmaceutical Expenditure by Country Income Level, 2005–06 37 3.3 Medicines in Countries’ International Trade, Exports minus Imports, 2009 38 3.4 Evolution of the Pharmaceutical Sector in Countries of Different Income Levels 40 4.1 The Relationship of Pharmaceutical Sector Problems to Ultimate Performance Goals 57 5.1 Pharmaceutical Performance Diagnostic Tree 77 5.2 Schematic Overview of the Determinants of System Performance 83 viii Contents 5.3 The Effect of Alternative Quality Improvement Strategies: The “Rotten Apple” View 84 5.4 The Effect of Alternative Quality Improvement Strategies: The Systems View 85 7.1 National Health Insurance Coverage for Countries by Region 107 7.2 Commodity Logistics System in Kenya 116 8.1 Private Sector Patient Prices for Selected Medicines in Pakistan Compared to International Reference Prices 135 9.1 The Six Keys to Organizational Performance 144 10.1 The Regulatory Cycle 167 D1 Current Public Health Sector Distribution System 236 D2 Unfi lled Posts in the Health Sector 241 F1 Tiers of Drug Retailers 257 F2 Accredited Drug Dispensing Outlet Program Outline 259 J1 Drug Costs as a Proportion of Total National Health Insurance Claims Costs 307 J2 Regional Analysis of National Health Insurance Per Capita Costs and Participation Rates 308 Tables 1.1 Top 10 Causes of Death by Income Group, 2004 2 1.2 Pharmaceutical Expenditures by Country Income Level, 2006 4 3.1 R&D Expenditures by Government
Load more

Recommended publications
  • Intellectual Property Rights and the Evergreening of Pharmaceuticals
    A Service of Leibniz-Informationszentrum econstor Wirtschaft Leibniz Information Centre Make Your Publications Visible. zbw for Economics Boscheck, Ralf Article — Published Version Intellectual property rights and the evergreening of pharmaceuticals Intereconomics Suggested Citation: Boscheck, Ralf (2015) : Intellectual property rights and the evergreening of pharmaceuticals, Intereconomics, ISSN 1613-964X, Springer, Heidelberg, Vol. 50, Iss. 4, pp. 221-226, http://dx.doi.org/10.1007/s10272-015-0546-y This Version is available at: http://hdl.handle.net/10419/172664 Standard-Nutzungsbedingungen: Terms of use: Die Dokumente auf EconStor dürfen zu eigenen wissenschaftlichen Documents in EconStor may be saved and copied for your Zwecken und zum Privatgebrauch gespeichert und kopiert werden. personal and scholarly purposes. Sie dürfen die Dokumente nicht für öffentliche oder kommerzielle You are not to copy documents for public or commercial Zwecke vervielfältigen, öffentlich ausstellen, öffentlich zugänglich purposes, to exhibit the documents publicly, to make them machen, vertreiben oder anderweitig nutzen. publicly available on the internet, or to distribute or otherwise use the documents in public. Sofern die Verfasser die Dokumente unter Open-Content-Lizenzen (insbesondere CC-Lizenzen) zur Verfügung gestellt haben sollten, If the documents have been made available under an Open gelten abweichend von diesen Nutzungsbedingungen die in der dort Content Licence (especially Creative Commons Licences), you genannten Lizenz gewährten Nutzungsrechte. may exercise further usage rights as specified in the indicated licence. www.econstor.eu DOI: 10.1007/s10272-015-0546-y Intellectual Property Ralf Boscheck Intellectual Property Rights and the Evergreening of Pharmaceuticals Escalating healthcare expenditures and the need to ensure access to affordable medicine in both emerging and emerged economies are fuelling calls to contain the so-called evergreening practices of drug producers around the world.
    [Show full text]
  • CARIBBEAN PHARMACEUTICAL POLICY.Indd
    <PAHO DOCUMENTOC IDENTIFICATION No> Caribbean PharmaceuticalPolicy Caribbean Pharmaceutical Policy Caribbean Pharmaceutical Policy Washington, D.C., 2013 PAHO HQ Library Cataloguing-in-PublicaƟ on Data ************************************************************************ Pan American Health OrganizaƟ on. Caribbean Community. Caribbean PharmaceuƟ cal Policy. Washington, DC : PAHO, 2013. 1. Drug and NarcoƟ c Control. 2. Health Policy, Planning and Management. 3. NaƟ onal Drug Policy. 4. Caribbean. I. Title. II. CARICOM. ISBN 978-92-75-11807-8 (NLM classifi caƟ on: QV55) The Pan American Health OrganizaƟ on welcomes requests for permission to reproduce or trans- late its publicaƟ ons, in part or in full. ApplicaƟ ons and inquiries should be addressed to the Department of Knowledge Management and CommunicaƟ ons (KMC), Pan American Health OrganizaƟ on, Washington, D.C., U.S.A. ([email protected]). The Department of Health Systems and Services (HSS) will be glad to provide the latest informaƟ on on any changes made to the text, plans for new ediƟ ons, and reprints and translaƟ ons already available. © Pan American Health OrganizaƟ on, 2013. All rights reserved. PublicaƟ ons of the Pan American Health OrganizaƟ on enjoy copyright protecƟ on in accordance with the provisions of Protocol 2 of the Universal Copyright ConvenƟ on. All rights are reserved. The designaƟ ons employed and the presentaƟ on of the material in this publicaƟ on do not imply the expression of any opinion whatsoever on the part of the Secretariat of the Pan American Health Orga- nizaƟ on concerning the status of any country, territory, city or area or of its authoriƟ es, or concerning the delimitaƟ on of its fronƟ ers or boundaries.
    [Show full text]
  • Pharmaceutical Good Manufacturing Practice Regulatory Affairs in Sudan
    ulatory A eg ffa R i l rs a : c i O t p Abdellah Abubaker et al., Pharmaceut Reg Affairs u Pharmaceutical Regulatory Affairs: e e n c A a 2016, 5:1 c m c r e ISSN:a 2167-7689 s h DOI: 10.4172/2167-7689.1000166 s P Open Access Research Article Open Access Pharmaceutical Good Manufacturing Practice Regulatory Affairs in Sudan: Continuous Debate between Regulatory Authority and Manufacturers Abubaker Abdellah1*, M I Noordin2,3, R Zaki4 and Ali Abedallah5 1Department of Pharmacy, Faculty of Medicine, University of Malaya, 50603, Kuala Lumpur, Malaysia 2Malaysian Institute of Pharmaceuticals and Nutraceuticals, Penang 3Department of Pharmacy, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia 4Faculty of Medicine, Department of Social and Preventive medicine, University of Malaya, Kuala Lumpur, Malaysia 5Faculty of Science, Department of Chemistry, University of Khartoum, Sudan *Corresponding author: Abubaker Abdellah, Department of Pharmacy, Faculty of Medicine, University of Malaya, 50603, Kuala Lumpur, Malaysia, Tel: +603-7967 5768; E-mail: [email protected] Received date: April 28, 2016; Accepted date: May 30, 2016; Published Date: June 01, 2016 Copyright: © 2016 Abubaker Abdellah et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Background: The implementation of GMP requirements in Sudan as developing country imposes pressure on both the manufacturers and regulatory authorities since resources are limited and additional regulatory and manufacturing facilities are required. Objective: The study aimed to assess the regulatory affairs of pharmaceutical good manufacturing practice in Sudan.
    [Show full text]
  • Overcoming Intellectual Property Monopolies in the COVID-19 Pandemic
    MSF Briefing Document July 2020 Overcoming intellectual property monopolies in the COVID-19 pandemic Médecins Sans Frontières (MSF) is responding to the global COVID-19 pandemic, providing treatment and care for people with COVID-19, protecting people living in vulnerable conditions, and ensuring uninterrupted essential health services for people suffering from other diseases.1 Having universal access to existing and future tools for treatment, diagnosis and prevention is critical. MSF has repeatedly witnessed how exclusive rights and monopolies granted to pharmaceutical corporations, resulting in high prices and blocking generic competition, have had a negative impact on our medical actions in different countries.2 For example, in the past, high prices for patented medicines have undermined the capacity of countries to provide access to treatment for HIV/AIDS, tuberculosis (TB), hepatitis C and cancer to all patients who need them. However, the impact of intellectual property (IP) monopolies is not limited to drugs. The availability of more affordable pneumococcal conjugate vaccine and human papillomavirus vaccine in low- and middle-income countries has been delayed due to unmerited patents on key technologies blocking follow-on producers.3 Intellectual property monopolies in the COVID-19 pandemic While several of the drugs being trialled as COVID-19 treatments are now off patent, patented drugs and experimental drugs are also being trialled, and some of which are under patent protection in many developing countries.4 With control over the market as a result of patents or other exclusive rights, pharmaceutical companies could determine how global production and supply chain are organised, who ultimately has access, who can produce medicines and where they can be supplied.
    [Show full text]
  • Evergreening" Metaphor in Intellectual Property Scholarship
    University of Missouri School of Law Scholarship Repository Faculty Publications Faculty Scholarship 2019 The "Evergreening" Metaphor in Intellectual Property Scholarship Erika Lietzan University of Missouri School of Law, [email protected] Follow this and additional works at: https://scholarship.law.missouri.edu/facpubs Part of the Food and Drug Law Commons, Intellectual Property Law Commons, and the Science and Technology Law Commons Recommended Citation Erika Lietzan, The "Evergreening" Metaphor in Intellectual Property Scholarship, 53 Akron Law Review 805 (2019). Available at: https://scholarship.law.missouri.edu/facpubs/984 This Article is brought to you for free and open access by the Faculty Scholarship at University of Missouri School of Law Scholarship Repository. It has been accepted for inclusion in Faculty Publications by an authorized administrator of University of Missouri School of Law Scholarship Repository. For more information, please contact [email protected]. DATE DOWNLOADED: Wed Jan 20 13:42:00 2021 SOURCE: Content Downloaded from HeinOnline Citations: Bluebook 21st ed. Erika Lietzan, The "Evergreening" Metaphor in Intellectual Property Scholarship, 53 AKRON L. REV. 805 (2019). ALWD 6th ed. Lietzan, E. ., The "evergreening" metaphor in intellectual property scholarship, 53(4) Akron L. Rev. 805 (2019). APA 7th ed. Lietzan, E. (2019). The "evergreening" metaphor in intellectual property scholarship. Akron Law Review, 53(4), 805-872. Chicago 7th ed. Erika Lietzan, "The "Evergreening" Metaphor in Intellectual Property Scholarship," Akron Law Review 53, no. 4 (2019): 805-872 McGill Guide 9th ed. Erika Lietzan, "The "Evergreening" Metaphor in Intellectual Property Scholarship" (2019) 53:4 Akron L Rev 805. AGLC 4th ed. Erika Lietzan, 'The "Evergreening" Metaphor in Intellectual Property Scholarship' (2019) 53(4) Akron Law Review 805.
    [Show full text]
  • Download the Transcript
    DRUGS-2017/05/02 1 THE BROOKINGS INSTITUTION REINING IN PRESCRIPTION DRUG PRICES Washington, D.C. Tuesday, May 2, 2017 Introduction: LOUISE SHEINER Senior Fellow, Economic Studies Policy Director, Hutchins Center on Fiscal and Monetary Policy The Brookings Institution Paper: Framework for Negotiation in Part D of Medicare MODERATOR: PAUL B. GINSBURG Senior Fellow, Economic Studies Leonard D. Schaeffer Chair in Health Policy Studies Director, Center for Health Policy The Brookings Institution Presenters: RICHARD G. FRANK Margaret T. Morris Professor of Health Economics Department of Health Care Policy Harvard Medical School RICHARD J. ZECKHAUSER Frank P. Ramsey Professor of Political Economy Harvard Kennedy School of Government Paper: Can Importation Address High Generic Drug Prices? MODERATOR: PAUL B. GINSBURG Senior Fellow, Economic Studies Leonard D. Schaeffer Chair in Health Policy Studies Director, Center for Health Policy The Brookings Institution Presenters: THOMAS BOLLYKY Senior Fellow for Global Health, Economics and Development Council on Foreign Relations AARON KESSELHEIM Associate Professor of Medicine ANDERSON COURT REPORTING 706 Duke Street, Suite 100 Alexandria, VA 22314 Phone (703) 519-7180 Fax (703) 519-7190 DRUGS-2017/05/02 2 Brigham and Women’s Hospital and Harvard Medical School Paper: Removing Barriers to Competition in Pharmaceutical Markets MODERATOR: PAUL B. GINSBURG Senior Fellow, Economic Studies Leonard D. Schaeffer Chair in Health Policy Studies Director, Center for Health Policy The Brookings Institution Presenters:
    [Show full text]
  • Canada's Continuing Support of US Linkage Regulations For
    Marquette Intellectual Property Law Review Volume 15 | Issue 1 Article 1 I'm Still Your Baby: Canada's Continuing Support of U.S. Linkage Regulations for Pharmaceuticals Ron A. Bouchard University of Manitoba, Canada Follow this and additional works at: http://scholarship.law.marquette.edu/iplr Part of the Intellectual Property Commons Repository Citation Ron A. Bouchard, I'm Still Your Baby: Canada's Continuing Support of U.S. Linkage Regulations for Pharmaceuticals, 15 Intellectual Property L. Rev. 71 (2011). Available at: http://scholarship.law.marquette.edu/iplr/vol15/iss1/1 This Article is brought to you for free and open access by the Journals at Marquette Law Scholarly Commons. It has been accepted for inclusion in Marquette Intellectual Property Law Review by an authorized administrator of Marquette Law Scholarly Commons. For more information, please contact [email protected]. I’M STILL YOUR BABY: CANADA’S CONTINUING SUPPORT OF U.S. LINKAGE REGULATIONS FOR PHARMACEUTICALS RON A. BOUCHARD∗ ABSTRACT ...................................................................................................... 72 INTRODUCTION ............................................................................................. 73 I. REVIEW OF EMPIRICAL STUDIES............................................................ 77 A. Study 1 ........................................................................................... 77 B. Study 2 ............................................................................................ 83 C. Study
    [Show full text]
  • Pharmaceutical Policy in China
    Pharmaceutical policy in China Challenges and opportunities for reform Elias Mossialos, Yanfeng Ge, Jia Hu and Liejun Wang Pharmaceutical policy in China: challenges and opportunities for reform Pharmaceutical policy in China: challenges and opportunities for reform Elias Mossialos, Yanfeng Ge, Jia Hu and Liejun Wang London School of Economics and Political Science and Development Research Center of the State Council of China Keywords DRUG AND NARCOTIC CONTROL PHARMACEUTICAL PREPARATIONS DRUG COSTS DRUG INDUSTRY HEALTH CARE REFORM HEALTH POLICY CHINA © World Health Organization 2016 (acting as the host organization for, and secretariat of, the European Observatory on Health Systems and Policies) All rights reserved. The European Observatory on Health Systems and Policies welcomes requests for permission to reproduce or translate its publications, in part or in full. Address requests about publications to: Publications, WHO Regional Office for Europe, UN City, Marmorvej 51, DK-2100 Copenhagen Ø, Denmark. Alternatively, complete an online request form for documentation, health information, or for permission to quote or translate, on the Regional Office web site (www.euro.who.int/pubrequest). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the European Observatory on Health Systems and Policies concerning the legal status of any country, territory, city or area or of its authorities, or concern- ing the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the European Observatory on Health Systems and Policies in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • World Bank Document
    HNP Brief #3 Pharmaceuticals: Local Manufacturing March 2005 Public Disclosure Authorized Introduction These numbers would look different if units (tablets) were counted instead of sales value. Middle income Pharmaceuticals are essential in every health care countries with large populations would take up a much system. The objective of pharmaceutical policy is to larger share, based on large volume / low cost markets make sure that there is a reliable supply of good quality for drugs in these countries (unfortunately, reliable data medicines at affordable prices. Local manufacturing is are not available because these numbers are not very sometimes offered as a potential solution to the relevant for industry decision makers). The large home “access” problem. Supporters of this concept suggest market allows manufacturers in India and China to that local production in a developing country should produce at low unit cost and exploit economies of scale. result in a cheaper final product. Skeptics argue that Given that drugs can be moved easily around the globe, small manufacturing units don’t achieve economies of if there were no or few barriers to importing, registration, scale, and that higher unit costs outweigh potential marketing and distribution, presumably, it would be hard Public Disclosure Authorized advantages such as lower transportation costs.[1] to beat Indian and Chinese manufacturers on price (although there may be lower price manufacturers who Another factor in this discussion is the TRIPS do not meet quality standards). Any market analysis that agreement. TRIPS requires all countries (except the is done to establish the business case for least developed) to introduce patents for pharmaceutical local manufacturing should recognize pharmaceuticals in 2005.
    [Show full text]
  • In Re: Glaxosmithkline Plc Securities Litigation 05-CV-3751
    UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK __________________________________________ ) In re: GlaxoSmithKline plc Securities ) Civil Action No. 05 CIV. 3751 (LAP) Litigation ) ) DEMAND FOR JURY TRIAL __________________________________________) CONSOLIDATED SECOND AMENDED COMPLAINT JURISDICTION AND VENUE 1. The claims asserted herein arise under §§ 10(b) and 20(a) of the Securities Exchange Act of 1934 (“1934 Act”) and Rule 10b-5. Jurisdiction is conferred by § 27 of the 1934 Act, and 28 U.S.C. §1331. Venue is proper here pursuant to § 27 of the 1934 Act. GlaxoSmithKline plc and SmithKline Beecham Corporation doing business as GlaxoSmithKline plc (collectively “GSK”) is headquartered in London, England, but conducts business in this District. GSK’s ADRs trade on the New York Stock Exchange headquartered in this District. THE PARTIES 2. Lead Plaintiff Joseph J. Masters (“Plaintiff”) acquired publicly traded securities of GSK during the Class Period and was damaged thereby. 3. Defendant GlaxoSmithKline plc is a public company. GlaxoSmithKline plc’s ADRs trade in an efficient market on the NYSE under the symbol “GSK.” GlaxoSmithKline plc’s ordinary shares trade in an efficient market on the London Stock Exchange. Defendant SmithKline Beecham Corporation is a Delaware corporation, which is a wholly-owned subsidiary of GlaxoSmithKline plc. GlaxoSmithKline plc was created in December 2000 when Glaxo Wellcome merged with SmithKline Beecham. Both GlaxoSmithKline plc and SmithKline Beecham, as well as all of their predecessors, subsidiaries and successors, are referred to herein collectively as “GSK.” 4. Defendant Jean-Pierre Garnier (“Garnier”) was CEO and Chairman of GSK throughout the Class Period. By reason of his position, Garnier had access to material inside information about GSK and was able to control directly or indirectly the acts of GSK and the contents of the representations disseminated during the Class Period by or in the name of GSK.
    [Show full text]
  • Evergreening and Patent Cliff Hangers CRISPR/Cas9 System and Gene
    Evergreening and patent cliff CRISPR/Cas9 system and gene Being equitable about hangers editing tools equivalents Ove Granstrand Thomas Hedner and Jean Lyckel John Hornby Page 4 Page 12 Page 24 Second medical use claims Do rules experience culture The patentability of Dosage and scope of protection shock? Regimes Clara Berrisch Lisa West Åkerblom Ester-Maria Elze Page 38 Page 48 Page 60 Safeguarding public health In pursuit of Robinson Crusoe The CJEU clarifies the effects in the wake of hegemonic Kristina Björnerstedt of skinny labelling intellectual property rights and Gunnel Nilsson Sofia Bergenstråhle Katarina Foss-Solbrekk Page 94 and Valter Gran Page 76 Page 98 Editorial Preface “Some industries are different but some are more different than others. The discusses how developing countries’ access to medicines is EDITOR-IN-CHIEF pharmaceutical industry fits the latter category” (Scherer 1996:336). There is impeded by the patent system as well as how flexibilities in really no other industry where the nature of the products, the economics of the international and national legal framework contribute Silvia A. Carretta research and development as well as the market structure and the societal to this end. The article shows that while exceptions to implications of the industry’s strategic decisions are as unique as in the patent rights might not be as effective, they have however pharmaceutical industry. Furthermore, there is no other industry that tests triggered a very interesting development of voluntary the boundaries and effects of intellectual property (IP) rights on a national and licensing, a company-centered initiative providing access international level as the pharmaceutical industry.
    [Show full text]
  • Creditor Rights and Allocative Distortions – Evidence from India
    Creditor Rights and Allocative Distortions { Evidence from India Nirupama Kulkarni CAFRAL (Reserve Bank of India) April 5, 2018 Creditor rights and Allocative Distortions I Large literature on creditor rights and impact on credit access I +: Due to higher payoffs (La Porta et. al (1998)). I −: Due to liquidation bias ((Hart and Moore (1994), Vig (2012)). I −: Heterogeneous impact (Lilienfeld-Toal, Mookherjee and Visaria (2012)). I This paper: focuses on the general equilibrium effects of creditor rights. I Delays in creditors' ability to seize defaulters' assets prevents reallocation of resources to their best use. I # creative destruction =) spurious allocation of resources. I \Evergreening" and \zombie" distortions (Caballero et al. (2008)). Do improvements in creditor rights lead to a better allocation of debt (and other resources)? This paper . My setting: Exploit a collateral reform in 2002 in India that made it easier for creditors to seize secured assets. I Step 1: Examine reallocation of debt away from low quality borrowers to high quality borrowers (Partial Equilibrium). I Step 2: Examine whether this is partly driven by the reduction in zombie firms. I Step 3: Examine spillovers on non-zombies due to reduction in zombie distortions (General Equilibrium). I Step 4: Examine productive efficiency at the industry level. Preview of Findings 1. Reallocate secured debt away from \low quality" borrowers: # INR 39 million (75 %). I No similar impact on unsecured borrowing, " in interest rates by 72 bps =) NOT driven by liquidation bias. 2. 59% reduction in secured borrowing due to reduction in zombie lending (\evergreening"). 3. Spillover effects on non-zombies due to reduction in zombie distortions.
    [Show full text]